Dr. Mayer Discusses Patient Selection for Emerging Therapies in Patients With ER+ mBC
Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).
Mayer believes it is not yet known who benefits from these targeting agents. There is phase II data for CDK4/6 inhibition in the first-line setting, which is encouraging because the preliminary results showed an improvement in progression-free survival, adds Mayer.
However, the phase III data does not yet have complete mature results, so it is difficult to determine whether or not the combination will yield an overall survival advantage.
Ingrid A. Mayer, MD, MSCI, co-leader and clinical director, Breast Cancer Research Program, chair, Data and Safety Monitoring Committee, associate professor of medicine (hematology/oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
